Expensive and softening.

Trading above fair value while the fundamentals weaken — little to like right now.

Price $72.80 taken 2026-11-15 · market cap about $11B
Fair value $32 range $24 to $44 · from the FY26 annual report
Margin of safety −56%, above fair value no margin of safety · the price sits above fair value

The five checks

2 good · 3 warning

  • Warning
    Overvalued
    Fair value ~$32 vs $73 — trading 56% above what the math supports.
  • Warning
    Price assumes a big acceleration
    You'd need ~16%/yr free-cash-flow growth to justify today's price; it has done 6.8%/yr lately.
  • Warning
    Revenue shrinking
    Down 0.4% last year — cheap may mean broken.
  • Good
    Cash flow compounding
    Free cash flow up ~6.8%/yr — the engine is growing.
  • Good
    Fortress balance sheet
    Net cash positive (+$0B) — little solvency risk.

Price against fair value

What today's price assumes

Hold the price fixed and work backwards: how fast would free cash flow have to grow for $73 to make sense?

The price needs ~16% a year
Bio-Techne has delivered 6.8% a year over the last three years

Price assumes a big acceleration.

Where this number comes from →

How fair value is calculated

No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.

  1. Free cash flow, FY26Operating cash flow less capital spending, from the annual report$0B
  2. Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$2B
  3. Everything after year tenGrowing 2.5% a year, counted the same way+ $3B
  4. The business, in today's money$5B
  5. Add net cashCash and securities less borrowings and finance leases+ $0B
  6. Divide by the shares on file÷ 0.157B

Fair value per share$32

If our assumptions are wrong

Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $24 to $44 range comes from.

3% growth5% growth7% growth
8% discount$32$38$44
9% discount$27$32$37
10% discount$24$28$32

The blue cell is the published method. Every cell sits below today’s price.

Free cash flow, ten years

$ billions · Form 10-K

$0.1B FY17 $0.1B FY18 $0.2B FY19 $0.1B FY20 $0.3B FY21 $0.3B FY22 $0.2B FY23 $0.2B FY24 $0.3B FY25 $0.3B FY26
  1. FY26 $0.3B
  2. FY25 $0.3B
  3. FY24 $0.2B
  4. FY23 $0.2B
  5. FY22 $0.3B
  6. FY21 $0.3B
  7. FY20 $0.1B
  8. FY19 $0.2B
  9. FY18 $0.1B
  10. FY17 $0.1B

What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.

How this was built. Every figure is computed from Bio-Techne Corporation's SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY26 annual report and change only when a new one is filed. Price of $72.80 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.

Read Bio-Techne another way

TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →